Effect of Methylprednisolone in treatment of COVID-19 patients
Phase 2
- Conditions
- the 2019 novel Corona virus (COVID-19).COVID-19 confirmed by laboratory testing.U07.1
- Registration Number
- IRCT20200204046369N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
RT-PCR documented SARS-CoV-2 carriage in a nasopharyngeal and oropharyngeal sample at admission
Age over 18 years old
O2 saturation of less than 92 in room air
Hospitalized patients
Exclusion Criteria
A known contraindication to treatment with the steroid
Breastfeeding and pregnant patients
Uncontrolled diabetes mellitus
Uncontrolled hypertension
patients who had previously been treated with steroids for any reason
O2 Saturation of above 92 in room air
Dissatisfaction with the study enrollment
Immunodeficiency disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The all-cause mortality in 28 days. Timepoint: 28 days. Method of measurement: Clinical follow-up.;Clinical status. Timepoint: 5 and 10 days after intervention. Method of measurement: 9-points WHO ordinal scale.
- Secondary Outcome Measures
Name Time Method Intubation and need for ventilation, and also admission to ICU. Timepoint: 5 and 10 days after intervention. Method of measurement: Clinical follow-up.;Duration of hospital admission. Timepoint: 5 and 10 days after intervention. Method of measurement: Clinical follow-up.